[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335184-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335184-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nusap1-promotes-gastric-cancer-radioresistance-by-inhibiting-ubiquitination-of-anxa2-and-is-suppressed-by-mir-129-5p","NUSAP1 promotes gastric cancer radioresistance by inhibiting ubiquitination of ANXA2 and is suppressed by miR-129-5p","","Radiotherapy is a key strategy for advanced gastric cancer, but radioresistance limits clinical benefit. This study investigates how nucleolar and spindle associated protein 1 (NUSAP1) contributes to gastric cancer (GC) radioresistance, a mechanism previously unclear. A meta-analysis assessed NUSAP1 prognostic value, while experiments evaluated radiosensitivity, DNA damage repair, apoptosis, and protein interactions. Results show NUSAP1 is linked to worse survival, promotes resistance via stabilizing ANXA2, and is negatively regulated by miR-129-5p.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nusap1-promotes-gastric-cancer-radioresistance-by-inhibiting-ubiquitination-of-anxa2-and-is-suppressed-by-mir-129-5p/335184/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nusap1-promotes-gastric-cancer-radioresistance-by-inhibiting-ubiquitination-of-anxa2-and-is-suppressed-by-mir-129-5p/335184.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is radioresistance a problem in advanced gastric cancer?","Question",{"text":63,"@type":64},"Radioresistance reduces the effectiveness of radiotherapy. As a result, tumors can recur locally and patient outcomes are limited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the meta-analysis reveal about NUSAP1?",{"text":68,"@type":64},"Higher NUSAP1 expression predicted worse overall survival (OS) and disease-free survival (DFS) without significant statistical heterogeneity.",{"name":70,"@type":61,"acceptedAnswer":71},"How does NUSAP1 regulate radioresistance mechanistically?",{"text":72,"@type":64},"NUSAP1 interacts with ANXA2 and protects it from protein degradation by inhibiting ANXA2 ubiquitination. NUSAP1 also is targeted and negatively regulated by miR-129-5p.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335184,1790786566,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of Cancer Research and Clinical Oncology (2024) 150:406  \n[https://doi.org/10.1007/s00432-024-05927-8](https://doi.org/10.1007/s00432-024-05927-8)  \nRESEARCH  \nNUSAP1 promotes gastric cancer radioresistance by inhibiting ubiquitination ofANXA2 and is suppressed by miR-129-5p  \nYugang Ge1 · Biao Wang2 · Jian Xiao3 · Hongshuai Wu4 · Qing Shao1  \nReceived: 26 July 2024 / Accepted: 16 August 2024 / Published online: 30 August 2024 © The Author(s) 2024  \nAbstract  \nBackground Radiotherapy is an important strategy for the treatment of advanced gastric cancer (GC), while the radioresistance limits its effectiveness. Nucleolar and spindle associated protein 1 (NUSAP1) was implicated in cancer progression and chemoresistance. However, the underlying mechanisms of NUSAP1 influencing GC radioresistance remain largely unknown.  \nMethods Meta-analysis was conducted to systematically evaluate the prognostic value of NUSAP1 in human cancers. Gene set enrichment analysis (GSEA) was conducted using The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO) datasets. MRNA and protein expressions were detected by qRT-PCR and western blot, respectively. The radiosensitivity of GC cells was observed by colony formation, flow cytometry, comet, immunofluorescence, and animal assays. Immunoprecipitation assay and mass spectrometry were utilized to identify protein associations. MiRNAs binding with NUSAP1 were determined by starbase prediction, luciferase reporter, and RNA immunoprecipitation (RIP) assays.  \nResults NUSAP1 high expression predicted worse overall survival (OS) and disease-free survival (DFS) with no statistical heterogeneity through the meta-analysis. Downregulation of NUSAP1 significantly increased GC radiosensitivity by inhibiting colony formation, DNA damage repair, and promoting apoptosis following irradiation. Additionally, NUSAP1 silencing combined with radiation resulted in a synergistic anti-tumor effect in xenograft mouse model. Mechanistically, NUSAP1 interacted with ANXA2, protecting it against protein degradation via impeding its ubiquitination process. NUSAP1 was confirmed as a target of miR-129-5p and negatively regulated by it.  \nConclusion Our results suggested that NUSAP1 enhanced the radioresistance of GC cells. NUSAP1 could be a promising target to increase GC radiosensitivity.  \nKeywords NUSAP1 · Gastric cancer · Radioresistance · ANXA2  \nYugang Ge, Biao Wang and Jian Xiao contributed equally to this study.  \n􀀍 Qing Shao [jyqingshao@sina.com](jyqingshao@sina.com)  \n1 Department of General Surgery, Jiangyin People’s Hospital, The Affiliated Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, Jiangsu Province, China  \n2 Department of Oncology, First People’s Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China  \n3 Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China  \n4 Wuxi Key Laboratory of Biomaterials for Clinical Application, Department of Central Laboratory, Jiangyin Clinical College of Xuzhou Medical University, Wuxi, China  \nIntroduction  \nGastric cancer (GC) ranks fifth in the incidence of all malignant tumors and third in cancer-related deaths around the world (Smyth et al. 2020). With the increasing understanding of its pathogenesis, multiple strategies have been used in the diagnosis and treatment of GC, including surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy ( Sexton, Al Hallak, Diab, & Azmi, 2020) . The five-year survival rate of early-stage GC patients undergoing surgery can reach 90 to 100%, even so, patients suffering from advanced GC possess a five-year survival rate of less than 30%( Song et al. 2017). In recent years, with the rapid development of radiotherapy equipment and technology, more and more attention has been paid to the role of radiotherapy in the comprehensive treatment of GC. Various  \nstudies have shown that radiotherapy","cbCaiirShJ7KvkTS","https://ap.wps.com/l/cbCaiirShJ7KvkTS","pdf",9325470,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why is radioresistance a problem in advanced gastric cancer?\",\"answer\":\"Radioresistance reduces the effectiveness of radiotherapy. As a result, tumors can recur locally and patient outcomes are limited.\"},{\"question\":\"What did the meta-analysis reveal about NUSAP1?\",\"answer\":\"Higher NUSAP1 expression predicted worse overall survival (OS) and disease-free survival (DFS) without significant statistical heterogeneity.\"},{\"question\":\"How does NUSAP1 regulate radioresistance mechanistically?\",\"answer\":\"NUSAP1 interacts with ANXA2 and protects it from protein degradation by inhibiting ANXA2 ubiquitination. NUSAP1 also is targeted and negatively regulated by miR-129-5p.\"}]","NUSAP1 promotes gastric cancer radioresistance by inhibiting ubiquitination of ANXA2 and is suppressed by miR-129-5p | PDF",1790009980,43]